Mid-Stage Trial Shows Shionogi’s Peramivir Equal to Tamiflu, GSK’s Relenza
This article was originally published in PharmAsia News
Executive Summary
A Phase II trial in Japan has shown the drug peramivir developed by Japan's Shionogi and U.S.-based BioCryst effective in reducing flu symptoms. Researchers said the drug appears to be as effective as Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir), the top drugs now used to treat influenza. Peramivir was tested against the other drugs in two different doses, using the same test the other drugs had faced. The head researcher said Shionogi's drug should be a good option for flu patients. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.